期刊文献+

血小板参数预测氯吡格雷抵抗的可行性研究 被引量:1

下载PDF
导出
摘要 目的探讨用血小板参数预测氯吡格雷抵抗的可行性。方法选取2013年1月-2014年9月期间确诊为冠心病并行经皮冠状动脉介入治疗(PCI)的患者67例,所有患者术前均给予氯吡格雷300 mg,术后给予氯吡格雷75 mg/d持续治疗。检测所有患者服药前、术后血小板聚集率及血常规。以血小板聚集抑制率≤10%定义为氯吡格雷抵抗,并依此分为氯吡格雷抵抗组和氯吡格雷反应正常组,分析两组患者的血小板参数情况。结果 67例患者中发生氯吡格雷抵抗21例,氯吡格雷反应正常46例,两组患者的血小板参数中平均血小板体积(MPV)和大血小板比率(0P-LCR)差异均有统计学意义(P〈0.05)。结论血小板参数中MPV和P-LCR可以作为氯吡格雷抵抗的预测因素。
机构地区 郑州市中医院
出处 《中国处方药》 2016年第1期49-50,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献8

  • 1Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time- Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation, 2011,124 (10) : 1132-1137.
  • 2M tiller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non- responders among patients with stable angina pectoris scheduled for elective coronary stent placement.ThrombHaemost, 2003, 89 (5) : 783-787.
  • 3Ari H, Ozkan H, Karacinar A, et al. The EFFect of high- dose ClopldogreltreatmENT in patients with clopidogrel resistance (theEFFICIENT trial) .Int J Cardiol, 2012, 157 (3) : 374-380.
  • 4崔同涛,于汇民,董太明,张斌,严红,乌汉东,廖洪涛,郭伟,靳立军.二磷酸腺苷诱导血小板聚集率与急性冠状动脉综合征患者支架置入预后的关系[J].中国介入心脏病学杂志,2012,20(6):301-306. 被引量:13
  • 5沈卫峰.“2013年ACCF/AHA ST段抬高型心肌梗死处理指南”点评[J].国际心血管病杂志,2013,40(1):1-2. 被引量:14
  • 6Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.J Am CollCardiol, 2008, 52 (9) : 743-749.
  • 7Giles H, Smith RE, Martin JF.Platelet glycoprotein II b-Ilia and size are increased in acute myocardial infarction..Eur J Clin Invest, 1994, 24 ( 1 ) : 69-72.
  • 8Jakubowski JA, Adler B, Thompson CB, et al. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction.J Lab Clin Med, 1985, 105 (2) : 271-276.

二级参考文献23

  • 1Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. EurJ Cardiothorac Surg, 2010,38 Suppl , Sl?S52.
  • 2Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI -CURE study. Lancet, 2001,358 :527-533.
  • 3Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals.J Am Coli Cardiol, 2005,45 :246-251.
  • 4SnoepJD, Hovens MM, EikenboomJC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting , a systematic review and meta-analysis. Am HeartJ, 2007,154 :221-231.
  • 5O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel , does one size fit all? Circulation, 2006,114: e600-e606.
  • 6Cuisset T , Frere C, QuiliciJ, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost, 2007,97 :282-287.
  • 7Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost, 2007,98 :707-709.
  • 8Gurbel P A, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease.J Am Coli Cardiol, 2007,50: 1822-1834.
  • 9Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Eng!J Med, 2009 ,360 :363-375.
  • 10Kubota T,Chiba K, Ishizaki T. GenotypingofS-mephenytoin4'?hydroxylation in an extendedJapanese population. Clin Pharmacol Ther, 1996,60 :661-666.

共引文献22

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部